Research Use Only. This compound is not intended for human consumption or therapeutic use.
Where to Buy PNC-27: Vendor Comparison & Research Info
PNC-27 is a synthetic anti-cancer peptide that binds HDM-2 and thus prevents its interaction with the p53 tumor suppressor protein. Research shows that it selectively kills cancer cells by inducing membranolysis (destruction of the cell membrane).
What is PNC-27?
What is PNC-27?
PNC-27 is a synthetically created peptide designed to specifically target and destroy cancer cells. It is a member of the PNC set of investigational proteins designed to attach to malformed (cancerous) cells and cause them to die through cell necrosis, all while leaving normal, healthy cells intact and unharmed.
The PNC-27 peptide contains an HDM-2 binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain. This has been found to enable the peptide to bind to and kill cancer cells through membranolysis, or disruption of the cell membrane.
Through research and study on animal subjects, the PNC-27 peptide has been shown to be highly effective in selectively targeting a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines.
PNC-27 Peptide
Molecular formula: C188H293N53O44S Molar Mass: 4031.7
How Does the PNC-27 Peptide Work?
PNC proteins were first theorized and created in 2000 by Drs. Matthew Pincus and Joseph Michl at the SUNY Downstate Medical Center in New York. Although they were originally intended to combat HIV, PNC-27 showed a remarkable ability to bind to cancer cells, causing them to die, while leaving healthy cells undamaged.
The PNC-27 cancer peptide is a nontoxic compound that causes the death of cancer cells only, leaving all other healthy cells unaffected. It is able to do this by attaching to the membranes of the individual cancer cells, creating holes in those membranes. As a result of the holes, rapid implosion occurs, leading to swift cell death due to the osmotic pressure difference in the inside vs. outside of the tumor cells.
PNC-27 accomplishes this due to its affinity for binding to a protein called HDM-2. Cancer cells have HDM-2 in their cell membranes. When the PNC-27 peptide is administered, it immediately travels to the HDM-2 located in the membranes of cancerous cells. By binding to them, it creates pores or holes in the cell membrane, causing “membranolysis,” or death of the cell membrane. This in turn leads to the destruction of the cancer cell.
Clinical Studies of the PNC-27 Peptide
In a paper published by the American Association for Cancer Research in 2010, Drs. Ehsan Sarafraz-Yazdi et al. revealed in depth how the PNC-27 cancer peptide exerted its effects and what its novel mechanism of action meant for the field of cancer research.[5] The paper’s authors reported that the peptide’s mechanism of action is due to the formation of oligomeric pores in the plasma membrane of tumor cells. Concurrently, oligomeric pores are not formed in untransformed, or non-tumor, cells. Further, they noted that it has been shown that MDM2 as a targeting molecule leads to PNC-27 selectivity towards cancer cells by its mis-localization to cancer cell plasma membranes.
Researchers concluded that these findings are descriptive of the unique localization of MDM2 variants in the plasma membranes of cancerous cells.[5] Further, they stated that this knowledge may hint at great promise for the PNC-27 peptide as a future anti-cancer drug pending clinical trials.
The PNC-27 research peptide has even been the subject of a fascinating Ted Talk. It can be seen conducted by Dr. Sarafraz-Yazdi, an Assistant Professor in the Division of Gynecologic Oncology at The State University of New York (SUNY).
PNC-27 Peptide Reviews
When the PNC-27 peptide is administered in animal studies, certain aspects have been noted in successful outcomes. Researchers have noted pain levels subjectively drop in a mean time of about a week. By the 3 week mark, animal subjects often present with flu-like symptoms, a likely indicator that subjects’ immune systems are responding to the death of cancer cells.
At 6 weeks, lactate dehydrogenase and bilirubin levels typically increase. Substantial tumor breakdown in successful research outcomes is often observed at around the 10 week mark. At this time, the tumors are noted to become softer and more pliable.
Some increase in the size of the tumor itself may be noted at this time. However, this is often due to inflammation because of immune system response. By the end of 3 months, researchers often notice animal study subjects to exhibit increased energy levels and reduced cancer-related symptoms.
PNC-27 Side Effects in Studies
PNC-27 side effects have been observed in animal studies. These have included skin and nose inflammation, watery eyes, dry skin, high blood pressure, headache, back pain, nosebleed, rectal bleeding, taste change, and too much protein in the urine.
PNC-27 Clinical Trials
In a 2009 study, researchers found that the previously established 3 dimensional structure of PNC-27’s p53 residues was directly superimposable on the structure for the same residues bound to HDM-2. This led the researchers to infer that PNC-27 could target HDM-2 in cancer cells’ membranes.
Notably, cancer cells have significant levels of HDM-2 in their membranes, while untransformed or noncancerous cells do not have significant levels of HDM-2. This allows the PNC-27 peptide to selectively target the cancerous cells, leaving undamaged the healthy surrounding tissue.
Upon further experimentation, it was discovered that by implanting untransformed cells not susceptible to PNC-27 with HDM-2 containing a membrane localization signal, these cells then became susceptible to PNC-27. As a result, this constituted further evidence that the PNC-27 peptide was able to selectively target HDM-2 in the membranes of cancer cells and destroy them via membranolysis, all while leaving healthy cells unharmed.
Further, in a 2010 study published in Cancer Chemotherapy and Pharmacology, researchers determined that PNC-27 exerts its cancer cell destroying effects as a whole peptide, not fragments. With the knowledge that the peptide forms transmembrane pores in the cancer cell membrane, researchers set out to determine whether these pores were created by parts of the peptide (fragments) or by the entire peptide itself.
During the experiment, it was shown that it was indeed the entire peptide that exerts its effects in the cell membrane of cancer cells. Further, it was observed that other nontransformed, or noncancerous, cells around the cancer cells “remained viable.” From the results of the experiment, researchers gleaned that the PNC-27 cancer peptide targeted specific markers in the membranes of cancer cells. Also, via this mechanism of action, PNC-27’s lifetime is increased.
PNC-27 Peptide Destroys Cancer Cells
In a 2006 study published in the International Journal of Cancer, researchers found that PNC-28, a forerunner to the PNC-27 peptide very similar in its structure and effects, was able to selectively inhibit pancreatic cancer cell growth in vivo. Study observers noted that the peptide induced necrosis, but not apoptosis, in a variety of tumor cell lines, including ras-transformed rat acinar pancreatic carcinoma cell line known as BMRPA1. In addition, the peptide had no effect on untransformed (normal) cells. As a result, researchers looked to determine if the cancer killing peptide could block the growth of pancreatic cancer cells in vivo.
Amazingly, researchers observed that when the cancer killing peptide was administered, it caused a complete blockade of any tumor growth during its 2-week period of administration and 2 weeks post-treatment. This was followed by weak tumor growth that plateaued at low tumor sizes compared with tumor growth in the presence of a control peptide.
Further, when the cancer killing peptide PNC-27 was administered after tumor growth had occurred at a remote site from the tumor, a decrease in tumor size followed by a slow increase in tumor growth that was “significantly slower than growth in the presence of control peptide” was observed to occur. Consequently, the study researchers concluded that the cancer killing peptide may be effective in treating cancer, especially if it was administered directly to the tumor itself.
PNC-27 Anti-Cancer Peptide Studies
In a more recent study conducted in 2014 and published in Annals of Clinical & Laboratory Science, researchers concluded that “the anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue mammalian leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.”[3]
Essentially, researchers built on knowledge gained from earlier experimentation that the PNC-27 peptide was able to destroy solid tissue tumor cells by binding to HDM-2 proteins in their cell membranes, an effect independent of p53 activity in those cells. The scientists sought to determine whether PNC-27 peptide would be similarly effective against non-solid tissue tumor cells.
This experiment would determine whether such non-solid tissue tumor cells actually expressed HDM-2 in their membranes in the first place (as the solid tissue cells were found to), and find whether PNC-27 could induce cell death in these cells through the same HDM-2 binding mechanism.
Incredibly, it was observed that these non-solid tumor cells do express HDM-2 in cell membranes.[3] Also, perhaps even more importantly, it was found that the PNC-27 peptide could induce cell necrosis through membranolysis via the same HDM-2 binding mechanism as in solid tissue tumor cells, independent of the p53 pathway.[3]
PNC-27 exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. PNC-27 for sale at Peptide review is limited to educational and scientific research only, not for human consumption. Only buy PNC-27 if you are a licensed researcher.
Article Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Where to Buy PNC-27 Online
| Action | ||||||
|---|---|---|---|---|---|---|
1 |  Peptide Hubs Verified | 9.0/10 Editorial Rating | $50.00 5mg vial | $10.00/mg | Out of Stock | Visit Site |
2 |  Dragon Peptides Verified | 9.0/10 Editorial Rating | $50.00 5mg vial | $10.00/mg | Out of Stock | Visit Site |
3 | 7.8/10 Editorial Rating | $19.99 83mg vial | $0.24/mg | In Stock | Visit Site | |
4 |  Pure Peptide Labs Verified | 5.0/10 Editorial Rating | $99.95 10mg vial | $10.00/mg | In Stock | Visit Site |
5 |  Core Peptides Verified | 4.0/10 Editorial Rating | $138.00 5mg vial | $27.60/mg | In Stock | Visit Site |
6 | N/A/10 Editorial Rating | $150.00 10mg vial | $15.00/mg | In Stock | Visit Site | |
7 | N/A/10 Editorial Rating | $129.00 5mg vial | $25.80/mg | In Stock | Visit Site | |
8 | N/A/10 Editorial Rating | $600.00 5mg vial | $120.00/mg | In Stock | Visit Site | |
9 | N/A/10 Editorial Rating | $58.00 5mg vial | $11.60/mg | In Stock | Visit Site | |
10 | N/A/10 Editorial Rating | $74.99 5mg vial | $15.00/mg | In Stock | Visit Site | |
11 | N/A/10 Editorial Rating | $130.00 10mg vial | $13.00/mg | In Stock | Visit Site | |
12 | N/A/10 Editorial Rating | $99.00 10mg vial | $9.90/mg | In Stock | Visit Site | |
13 |  Blue Line Research Verified | N/A/10 Editorial Rating | $85.00 mg vial | $/mg | In Stock | Visit Site |
Top-Ranked Vendor
COA Transparency
Score: 8/10
Testing Documentation & Verification
Peptide Hubs markets itself as a supplier of research peptides and related laboratory compounds. The company emphasizes product quality, purity standards, and analytical testing procedures designed to support research applications.
Product information is generally organized and includes technical details intended to help customers evaluate available compounds. The company promotes quality-control measures and manufacturing consistency across its portfolio.
While transparency appears solid, wider availability of batch-specific Certificates of Analysis (COAs), third-party laboratory testing reports, and independent verification documentation would further strengthen buyer confidence.
Assessment
Peptide Hubs demonstrates a clear commitment to quality standards, though expanded public testing documentation would improve overall transparency.
Reputation
Score: 8/10
Customer Feedback & Online Presence
Peptide Hubs maintains a professional online presence focused on research products and customer service. The company appears positioned toward researchers and buyers seeking access to popular peptide compounds and specialty research materials.
Its product presentation, organization, and focus on customer support contribute positively to credibility. The supplier has developed a growing presence within the research-compound marketplace.
Independent review volume appears moderate, and prospective buyers may benefit from conducting routine due diligence before large purchases.
Assessment
A professional business presentation and research-focused approach support a generally favorable reputation.
Pricing
Score: 9/10
Product Value & Cost Competitiveness
Pricing is one of Peptide Hubs' stronger competitive advantages. The company appears to offer competitive rates across a broad selection of research compounds.
Volume discounts, wholesale opportunities, and bundled purchasing options help improve value for repeat buyers and larger research projects.
Assessment
Competitive pricing and broad product availability create strong value for research customers.
Policies
Score: 8/10
Customer Protection & Transparency
Peptide Hubs provides customer-support channels and purchasing information intended to simplify the ordering process.
The company appears focused on maintaining responsive communication and a straightforward customer experience. Product information is generally easy to access and navigate.
More publicly available information regarding returns, refunds, warranties, and dispute-resolution procedures would further strengthen policy transparency.
Assessment
Customer-support accessibility contributes positively to buyer confidence.
Shipping
Score: 8/10
Delivery Coverage & Fulfillment
Shipping appears to be a reliable operational area. The company promotes order fulfillment services designed to support efficient delivery and customer satisfaction.
Secure packaging, shipment processing, and logistics support help improve the overall purchasing experience.
Assessment
Reliable fulfillment practices contribute positively to customer satisfaction.
Catalog
Score: 9/10
Product Selection & Inventory Depth
Peptide Hubs offers a broad range of peptide and research compounds.
Metabolic Research Products
Tirzepatide
Retatrutide
Semaglutide
Cagrilintide
Recovery & Regenerative Peptides
BPC-157
TB-500
GHK-Cu
KPV
Growth Hormone Research Products
Tesamorelin
Ipamorelin
CJC-1295
Sermorelin
Longevity & Cellular Research
MOTS-C
SS-31
NAD+ Related Compounds
Specialty Research Products
Peptide Blends
Experimental Research Compounds
Laboratory Support Materials
Assessment
The catalog provides strong coverage across several major peptide-research categories while supporting both individual and commercial purchasing needs.
What We Like
Strengths
Competitive pricing.
Broad peptide selection.
User-friendly website.
Growing market presence.
Variety of research compounds.
Wholesale purchasing options.
Customer-focused service.
Organized product catalog.
Research-oriented business model.
What Could Be Better
Areas for Improvement
More publicly available batch-specific COAs.
Expanded third-party testing visibility.
Greater independent customer-review volume.
Enhanced manufacturing transparency.
More detailed refund and return information.
Additional educational resources for researchers.
Online Ratings & Reviews
Key Positive Themes
Competitive pricing.
Broad product selection.
Easy ordering process.
Product availability.
Responsive support.
Key Negative Themes
Limited third-party review volume.
Desire for additional testing transparency.
More publicly available documentation requested.
Overall Public Sentiment
Overall sentiment appears generally positive, with customers appreciating product availability, affordability, and ease of purchasing.
Most Common Praise
Product variety.
Value for money.
Customer support.
Research-focused catalog.
Ordering convenience.
Most Common Concerns
Limited independent reviews.
Additional testing documentation desired.
Greater company transparency requested.
Brand Overview
Company Name
Peptide Hubs
Industry
Research Peptides, Biotechnology Products & Research Compounds
Main Products
Tirzepatide
Retatrutide
Semaglutide
Cagrilintide
BPC-157
TB-500
GHK-Cu
MOTS-C
Tesamorelin
CJC-1295
Headquarters
United States-Oriented Research Supply Business
Shipping Regions
Domestic and International Availability
Payment Methods
Online Payment Solutions
Alternative Payment Methods
Commercial Purchasing Arrangements
Company Summary
Peptide Hubs is a research-focused supplier offering peptides, research compounds, and related laboratory products. The company emphasizes accessibility, competitive pricing, and customer support while serving researchers and procurement customers seeking popular peptide compounds.
Its catalog includes compounds commonly used in metabolic, regenerative, hormonal, and longevity-related research. Through a combination of product variety and value-oriented pricing, the company aims to provide convenient access to research materials.
Final Verdict
Peptide Hubs offers a solid mix of affordability, catalog depth, and customer accessibility. The company's strongest advantages include competitive pricing, broad product availability, and a straightforward purchasing experience.
While expanded third-party testing transparency and a larger body of independent customer reviews would further strengthen credibility, Peptide Hubs presents a reasonable option for buyers seeking a wide selection of research compounds at competitive prices.
Final Rating: 8.4/10
Chemical Properties & Handling
Standard storage protocols for lyophilized peptides generally apply unless otherwise specified.
- Lyophilized (Powder): Store at -20°C for up to 3 years. Keep away from direct light and moisture.
- Reconstituted (Liquid): Store at 2-8°C (refrigerated) and use within 20-30 days to maintain stability.
Research Reviews
No Research Reviews Yet
Be the first to share your research protocol and vendor experience with PNC-27.
Best PNC-27 Vendors & Price Comparison
What is PNC-27?
PNC-27 is a synthetically created peptide designed to specifically target and destroy cancer cells. It is a member of the PNC set of investigational proteins designed to attach to malformed (cancerous) cells and cause them to die through cell necrosis, all while leaving normal, healthy cells intact and unharmed.
The PNC-27 peptide contains an HDM-2 binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain. This has been found to enable the peptide to bind to and kill cancer cells through membranolysis, or disruption of the cell membrane.
Through research and study on animal subjects, the PNC-27 peptide has been shown to be highly effective in selectively targeting a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines.
PNC-27 Peptide
Molecular formula: C188H293N53O44S Molar Mass: 4031.7
How Does the PNC-27 Peptide Work?
PNC proteins were first theorized and created in 2000 by Drs. Matthew Pincus and Joseph Michl at the SUNY Downstate Medical Center in New York. Although they were originally intended to combat HIV, PNC-27 showed a remarkable ability to bind to cancer cells, causing them to die, while leaving healthy cells undamaged.
The PNC-27 cancer peptide is a nontoxic compound that causes the death of cancer cells only, leaving all other healthy cells unaffected. It is able to do this by attaching to the membranes of the individual cancer cells, creating holes in those membranes. As a result of the holes, rapid implosion occurs, leading to swift cell death due to the osmotic pressure difference in the inside vs. outside of the tumor cells.
PNC-27 accomplishes this due to its affinity for binding to a protein called HDM-2. Cancer cells have HDM-2 in their cell membranes. When the PNC-27 peptide is administered, it immediately travels to the HDM-2 located in the membranes of cancerous cells. By binding to them, it creates pores or holes in the cell membrane, causing “membranolysis,” or death of the cell membrane. This in turn leads to the destruction of the cancer cell.
Clinical Studies of the PNC-27 Peptide
In a paper published by the American Association for Cancer Research in 2010, Drs. Ehsan Sarafraz-Yazdi et al. revealed in depth how the PNC-27 cancer peptide exerted its effects and what its novel mechanism of action meant for the field of cancer research.[5] The paper’s authors reported that the peptide’s mechanism of action is due to the formation of oligomeric pores in the plasma membrane of tumor cells. Concurrently, oligomeric pores are not formed in untransformed, or non-tumor, cells. Further, they noted that it has been shown that MDM2 as a targeting molecule leads to PNC-27 selectivity towards cancer cells by its mis-localization to cancer cell plasma membranes.
Researchers concluded that these findings are descriptive of the unique localization of MDM2 variants in the plasma membranes of cancerous cells.[5] Further, they stated that this knowledge may hint at great promise for the PNC-27 peptide as a future anti-cancer drug pending clinical trials.
The PNC-27 research peptide has even been the subject of a fascinating Ted Talk. It can be seen conducted by Dr. Sarafraz-Yazdi, an Assistant Professor in the Division of Gynecologic Oncology at The State University of New York (SUNY).
PNC-27 Peptide Reviews
When the PNC-27 peptide is administered in animal studies, certain aspects have been noted in successful outcomes. Researchers have noted pain levels subjectively drop in a mean time of about a week. By the 3 week mark, animal subjects often present with flu-like symptoms, a likely indicator that subjects’ immune systems are responding to the death of cancer cells.
At 6 weeks, lactate dehydrogenase and bilirubin levels typically increase. Substantial tumor breakdown in successful research outcomes is often observed at around the 10 week mark. At this time, the tumors are noted to become softer and more pliable.
Some increase in the size of the tumor itself may be noted at this time. However, this is often due to inflammation because of immune system response. By the end of 3 months, researchers often notice animal study subjects to exhibit increased energy levels and reduced cancer-related symptoms.
PNC-27 Side Effects in Studies
PNC-27 side effects have been observed in animal studies. These have included skin and nose inflammation, watery eyes, dry skin, high blood pressure, headache, back pain, nosebleed, rectal bleeding, taste change, and too much protein in the urine.
PNC-27 Clinical Trials
In a 2009 study, researchers found that the previously established 3 dimensional structure of PNC-27’s p53 residues was directly superimposable on the structure for the same residues bound to HDM-2. This led the researchers to infer that PNC-27 could target HDM-2 in cancer cells’ membranes.
Notably, cancer cells have significant levels of HDM-2 in their membranes, while untransformed or noncancerous cells do not have significant levels of HDM-2. This allows the PNC-27 peptide to selectively target the cancerous cells, leaving undamaged the healthy surrounding tissue.
Upon further experimentation, it was discovered that by implanting untransformed cells not susceptible to PNC-27 with HDM-2 containing a membrane localization signal, these cells then became susceptible to PNC-27. As a result, this constituted further evidence that the PNC-27 peptide was able to selectively target HDM-2 in the membranes of cancer cells and destroy them via membranolysis, all while leaving healthy cells unharmed.
Further, in a 2010 study published in Cancer Chemotherapy and Pharmacology, researchers determined that PNC-27 exerts its cancer cell destroying effects as a whole peptide, not fragments. With the knowledge that the peptide forms transmembrane pores in the cancer cell membrane, researchers set out to determine whether these pores were created by parts of the peptide (fragments) or by the entire peptide itself.
During the experiment, it was shown that it was indeed the entire peptide that exerts its effects in the cell membrane of cancer cells. Further, it was observed that other nontransformed, or noncancerous, cells around the cancer cells “remained viable.” From the results of the experiment, researchers gleaned that the PNC-27 cancer peptide targeted specific markers in the membranes of cancer cells. Also, via this mechanism of action, PNC-27’s lifetime is increased.
PNC-27 Peptide Destroys Cancer Cells
In a 2006 study published in the International Journal of Cancer, researchers found that PNC-28, a forerunner to the PNC-27 peptide very similar in its structure and effects, was able to selectively inhibit pancreatic cancer cell growth in vivo. Study observers noted that the peptide induced necrosis, but not apoptosis, in a variety of tumor cell lines, including ras-transformed rat acinar pancreatic carcinoma cell line known as BMRPA1. In addition, the peptide had no effect on untransformed (normal) cells. As a result, researchers looked to determine if the cancer killing peptide could block the growth of pancreatic cancer cells in vivo.
Amazingly, researchers observed that when the cancer killing peptide was administered, it caused a complete blockade of any tumor growth during its 2-week period of administration and 2 weeks post-treatment. This was followed by weak tumor growth that plateaued at low tumor sizes compared with tumor growth in the presence of a control peptide.
Further, when the cancer killing peptide PNC-27 was administered after tumor growth had occurred at a remote site from the tumor, a decrease in tumor size followed by a slow increase in tumor growth that was “significantly slower than growth in the presence of control peptide” was observed to occur. Consequently, the study researchers concluded that the cancer killing peptide may be effective in treating cancer, especially if it was administered directly to the tumor itself.
PNC-27 Anti-Cancer Peptide Studies
In a more recent study conducted in 2014 and published in Annals of Clinical & Laboratory Science, researchers concluded that “the anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue mammalian leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.”[3]
Essentially, researchers built on knowledge gained from earlier experimentation that the PNC-27 peptide was able to destroy solid tissue tumor cells by binding to HDM-2 proteins in their cell membranes, an effect independent of p53 activity in those cells. The scientists sought to determine whether PNC-27 peptide would be similarly effective against non-solid tissue tumor cells.
This experiment would determine whether such non-solid tissue tumor cells actually expressed HDM-2 in their membranes in the first place (as the solid tissue cells were found to), and find whether PNC-27 could induce cell death in these cells through the same HDM-2 binding mechanism.
Incredibly, it was observed that these non-solid tumor cells do express HDM-2 in cell membranes.[3] Also, perhaps even more importantly, it was found that the PNC-27 peptide could induce cell necrosis through membranolysis via the same HDM-2 binding mechanism as in solid tissue tumor cells, independent of the p53 pathway.[3]
PNC-27 exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. PNC-27 for sale at Peptide review is limited to educational and scientific research only, not for human consumption. Only buy PNC-27 if you are a licensed researcher.
Article Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Current Research & Evidence
Research evidence for PNC-27 has not yet been added.
Key Findings on PNC-27 Use
Key findings for PNC-27 have not yet been added.
Related Peptides in Peptide
BPC 157
In the stomach of every man lies a substance more powerful than he knows. BPC-157 derives from this source - gastric juice, that most unpoetic of origins for what may prove a considerable discovery. The synthetic version contains fifteen amino acids arranged with the precision nature reserves for her most essential works. It endures where other peptides fail.
MOTS-c
The Mitochondrial-Derived Peptide MOTS-c promotes metabolic homeostasis and longevity, improves exercise capacity, reduces obesity, insulin resistance and other disease processes such as osteoporosis .
GHK-Cu
(2mg x 60 Capsules) (Copper Tripeptide) GHK-Cu is a small, naturally occurring peptide with the ability to attenuate inflammation, improve antioxidant responses, and improve gene expression on a large scale. Research shows that this copper-chelating peptide may be of critical importance both in the prevention of neurodegenerative disease and as a tool for exploring pathophysiological mechanisms. Studies in mice have revealed that GHK-Cu can protect against neurological insults, improve wound healing, reduce rates of infection, and boost blood vessel growth.
TB-500
Thymosin Beta-4 is a 43 amino acid peptide sequence. In animal models, Thymosin Beta-4 has been shown to improve blood vessel growth, regulate wound healing, decrease inflammation, and reduce oxidative damage in the heart and central nervous system. Thymosin-beta-4 has a role in protection, tissue repair, regeneration and remodeling of injured or damaged tissues. It is also of active interest in anti-aging research.